Oscar Arrieta1, Andrés F Cardona2,3, Guillermo Bramuglia4,5, Graciela Cruz-Rico6, Luis Corrales7, Claudio Martín8, Victoria Imaz-Olguín9, Omar Castillo10, Mauricio Cuello11, Érica Rojas-Bilbao12, Gabriel Casas13, Cristina Fernández14, Osvaldo Arén Frontera14, Valeria Denninghoff15, Gonzalo Recondo15, Alejandro Avilés-Salas16, Luis-Alberto Mas-Lopez17, George Oblitas18, Leonardo Rojas19, Antonio Piottante20, Ernesto Jiménez-García21, Sergio Sánchez-Sosa22, Julia Sáenz-Frias23, Hernán Lupera24, Laura Alejandra Ramírez-Tirado6, Carlos Vargas2, Hernán Carranza2, Horacio Astudillo25, Laura Beatriz Wills3, Ernestina Pichelbaur4, Luis E Raez26. 1. Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico, oscararrietaincan@gmail.com. 2. Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia. 3. Foundation for Clinical and Applied Cancer Research-FICMAC, Bogotá, Colombia. 4. Pharmacy and Biochemistry Faculty, Universidad de Buenos Aires, Buenos Aires, Argentina. 5. Foundation "Investigar", Buenos Aires, Argentina. 6. Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico. 7. Medical Oncology Department, Hospital San Juan de Dios, San Jose, Costa Rica. 8. Medical Oncology Department, Thoracic Oncology Section, Instituto Fleming, Buenos Aires, Argentina. 9. Oncología Integral de Alta Especialidad, Hospital ABC, Mexico City, Mexico. 10. Internal Medicine-Medical Oncology Department, National Institute of Cancer, Panama City, Panama. 11. Medical Oncology Department, Universidad de la Republica-UdeLAR, Montevideo, Uruguay. 12. Pathology Department, Instituto de Oncología Angel H. Roffo, University of Buenos Aires, Buenos Aires, Argentina. 13. Pathology Department, Hospital Alemán, Buenos Aires, Argentina. 14. Pathology Department, Hospital Clínico de la Universidad de Chile, Santiago de Chile, Chile. 15. Centro de Estudios Médicos e Investigaciones Clínicas "Norberto Quirno" (CEMIC), Buenos Aires, Argentina. 16. Department of Pathology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico. 17. Instituto Nacional de Enfermedades Neoplásicas, Surquillo, Peru. 18. Medical Oncology Department, Thoracic Oncology Section, Instituto Oncologico "Dr. Luis Razetti", Caracas, Venezuela. 19. Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia. 20. Department of Pathology, Clínica las Condes, Santiago, Chile. 21. Técnicas Genéticas Aplicadas a la Clínica, Mexico City, Mexico. 22. Hospital Ángeles de Puebla. Escuela de Medicina UDLAP (Universidad de las Américas Puebla), Puebla, Mexico. 23. Centro Medico del Noreste, Unidad Médica de Alta Especialidad UMAE, Instituto Mexicano del Seguro Social, Monterrey, Mexico. 24. Department of Pathology, Hospital Metropolitano, Guayaquil, Ecuador. 25. Consejo de Nanopharmacia Diagnóstica, Mexico City, Mexico. 26. Memorial Cancer Institute, Memorial Healthcare System, Hollywood, Florida, USA.
Abstract
OBJECTIVE: Latin American countries are heterogeneous in terms of lung cancer incidence and exposure to potential carcinogens. We evaluated the frequency and clinical characteristics of ALK rearrangements (ALKr) in Latin America. METHODS: A total of 5,130 lung cancer patients from 10 Latin American countries were screened for inclusion. ALKr detection was performed by fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and real-time reverse transcriptase-polymerase chain reaction (RT-PCR) to assess method variability. Demographic and clinicopathologic characteristics were analyzed. RESULTS: Among the 5,130 patients screened, 8.4% (n = 433) had nonevaluable FISH tests. Evaluable FISH analyses revealed positive ALKr in 6.8% (320/4,697) of the study population, which included patients from 9 countries. ALKr distribution for each country was: Mexico 7.6% (79/1,034), Colombia 4.1% (10/242), Argentina 6.0% (153/2,534), Costa Rica 9.5% (13/137), Panama 4.4% (5/114), Uruguay 5.4% (2/37), Chile 8.6% (16/185), Venezuela 8.9% (13/146), and Peru 10.8% (29/268). RT-PCR showed high positive (83.6%) and negative (99.7%) predictive values when compared to the gold standard FISH. In contrast, IHC only showed a high negative predictive value (94.6%). CONCLUSIONS: Although there is a clear country and continental variability in terms of ALKr frequency, this difference is not significant and the overall incidence of ALKr in Latin America does not differ from the rest of the world.
OBJECTIVE: Latin American countries are heterogeneous in terms of lung cancer incidence and exposure to potential carcinogens. We evaluated the frequency and clinical characteristics of ALK rearrangements (ALKr) in Latin America. METHODS: A total of 5,130 lung cancerpatients from 10 Latin American countries were screened for inclusion. ALKr detection was performed by fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and real-time reverse transcriptase-polymerase chain reaction (RT-PCR) to assess method variability. Demographic and clinicopathologic characteristics were analyzed. RESULTS: Among the 5,130 patients screened, 8.4% (n = 433) had nonevaluable FISH tests. Evaluable FISH analyses revealed positive ALKr in 6.8% (320/4,697) of the study population, which included patients from 9 countries. ALKr distribution for each country was: Mexico 7.6% (79/1,034), Colombia 4.1% (10/242), Argentina 6.0% (153/2,534), Costa Rica 9.5% (13/137), Panama 4.4% (5/114), Uruguay 5.4% (2/37), Chile 8.6% (16/185), Venezuela 8.9% (13/146), and Peru 10.8% (29/268). RT-PCR showed high positive (83.6%) and negative (99.7%) predictive values when compared to the gold standard FISH. In contrast, IHC only showed a high negative predictive value (94.6%). CONCLUSIONS: Although there is a clear country and continental variability in terms of ALKr frequency, this difference is not significant and the overall incidence of ALKr in Latin America does not differ from the rest of the world.
Authors: Oscar Arrieta; Laura-Alejandra Ramírez-Tirado; Enrique Caballé-Perez; Alberto Mejia-Perez; Zyanya Lucia Zatarain-Barrón; Andrés F Cardona; Francisco Lozano-Ruíz; Manuel Segura-González; Graciela Cruz-Rico; Federico Maldonado; Rafael Rosell Journal: Thorac Cancer Date: 2020-02-19 Impact factor: 3.500
Authors: Tiago F Andreis; Bruno S Correa; Fernanda S Vianna; Fernanda De-Paris; Marina Siebert; Sandra Leistner-Segal; Eriza C Hahn; Jane M Ulbrich; Luis F R Rivero; Francine H De Oliveira; Vinícius Lorandi; Patricia Ashton-Prolla; Gabriel S Macedo Journal: J Glob Oncol Date: 2019-09
Authors: Lázaro Antonio Campanha Novaes; Luciane Sussuchi da Silva; Pedro De Marchi; Rodrigo de Oliveira Cavagna; Flavia Escremim de Paula; Maicon Fernando Zanon; Adriane Feijó Evangelista; Eduardo Caetano Albino da Silva; Vinícius Duval da Silva; Letícia Ferro Leal; Rui Manuel Reis Journal: Transl Lung Cancer Res Date: 2021-01